Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics
British Journal of Pharmacology · 2026-11 · 183 (22) · 6649-6655
DOI: 10.1111/bph.70256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 12.11.2025. Verfasst von Nathan M Alba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Burlington High School, Burlington, Massachusetts, USA. Hauptthemen laut MEDLINE: Proteomics, Interferons, Autoimmune Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Mendelian type I interferonopathies are autoimmune diseases caused by genetic mutations that result in upregulation of interferon signalling. Small molecules that modulate proteins encoded by these genes may drive anti‐tumour immunity in cancer patients by increasing interferon levels, but chemical probes and drugs are lacking. Covalent chemoproteomics and structural data were compiled to reveal ligandable cysteines, tyrosines and lysines across diverse proteins associated with interferonopathies. From this analysis, we identified several actionable targets, including ligandable sites on ADAR1, RNASEH2A and SAMHD1, and so our work provides a useful resource for future drug discovery efforts directed towards the development of immunotherapeutics. LINKED ARTICLES This article is part of a themed issue Re‐emergence of Covalent Modulation in Drug Discovery. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.22/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Burlington High School, Burlington, Massachusetts, USA.
- Winchester High School, Winchester, Massachusetts, USA.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
Zitieren
APA
Alba, N. M., Jones, C. R., Jones, F. L., & Jones, L. H. (2026). Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics. British Journal of Pharmacology, 183(22), 6649-6655. https://doi.org/10.1111/bph.70256
Vancouver
Alba NM, Jones CR, Jones FL, Jones LH. Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics. British Journal of Pharmacology. 2026;183(22):6649-6655. doi:10.1111/bph.70256
BibTeX
@article{Alba2026,
author = {Alba, Nathan M and Jones, Carys R and Jones, Ffion L and Jones, Lyn H},
title = {Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {22},
pages = {6649--6655},
doi = {10.1111/bph.70256}
}
EUVIMED